EA
AXDX

Emerald Acquisition’s Accelerate Diagnostics AXDX Stock Holding History

Emerald Acquisition’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$256K Buy
+938
New +$208K ﹤0.01% 2637

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's AXDX Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Accelerate Diagnostics (AXDX) in Q3 2016: 938 shares worth $256K. The stake represents ﹤0.01% of the portfolio and ranks #2637 among its holdings.

103 funds tracked by Wall St. Rank hold AXDX as of Q3 2016.

  • Emerald Acquisition held 938 shares of Accelerate Diagnostics worth $256K as of Q3 2016.
  • Accelerate Diagnostics was a new Emerald Acquisition position in Q3 2016.
  • Accelerate Diagnostics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2637 holding.
  • 103 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.